Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis
Alexandre E. Malek,Taha Al-Juhaishi,Denái R. Milton,Jeremy L. Ramdial,May Daher,Amanda L. Olson,Samer A. Srour,Gheath Alatrash,Betul Oran,Rohtesh S. Mehta,Issa F. Khouri,Qaiser Bashir,Nina Shah,Stefan O. Ciurea,Gabriela Rondon,Farzaneh Maadani,Chitra Hosing,David Marin,Partow Kebriaei,Katayoun Rezvani,Yago Nieto,Paolo Anderlini,Amin M. Alousi,Muhammad Salman Faisal,Muzaffar H. Qazilbash,Uday R. Popat,Richard E. Champlin,Elizabeth J. Shpall,Victor E. Mulanovich,Sairah Ahmed
DOI: https://doi.org/10.1038/s41409-024-02238-x
2024-02-15
Bone Marrow Transplantation
Abstract:Toxoplasma gondii is an opportunistic infection in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients and could lead to life-threatening complications such as pneumonia, meningoencephalitis, or disseminated disease with mortality rate of up to 60% [1, 2]. Toxoplasmosis usually occurs secondary to reactivation of latent Toxoplasma infection rather than through new encounter [3, 4]. The risk factors of Toxoplasma reactivation include Toxoplasma -seropositive allo-HCT recipients, seronegative donors, conditioning regimens containing anti-thymocyte globulin and myeloablative chemotherapy, umbilical cord blood or unrelated donor grafts, graft-versus-host disease (GVHD), immunosuppressive treatment, and lack of Toxoplasma antimicrobial prophylaxis [5,6,7,8]. The incidence of Toxoplasma reactivation after allo-HCT ranges between 0.3% and 8% in North America to around 11.6% in endemic European countries [2, 5, 8,9,10]. Allo-HCT recipients can develop either Toxoplasma infection, an asymptomatic parasitemia defined by positive Toxoplasma PCR test in blood only (with or without fever); or Toxoplasma disease which is a constellation of clinical and radiological evidence of end-organ damage along with positive Toxoplasma PCR in blood or in other body fluids or positive histopathological examination [2, 6, 11]. In this study, we aimed to describe the real-world experience of monitoring Toxoplasma PCR in blood of Toxoplasma -seropositive patients following allo-HCT, and to evaluate the risk factors associated with Toxoplasma reactivation.
oncology,immunology,hematology,transplantation